Forbes names ICON in list of Best Employers in America for Women

ICON recognised as top employer for women in anonymous survey of 75,000 employees

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been recognised in the 2020 Forbes List of America’s Best Employers for Women for the second consecutive year.

Forbes collaborated with market research firm Statista, surveying 75,000 Americans, including 45,000 women, working for businesses that employ more than 1,000 workers. The respondents spanned 31 industries and were asked to share their opinions on a series of statements about their respective employers’ culture, opportunities for career development, image, working conditions, salary and diversity.

“We’re delighted to be recognised in the Forbes list of Best Employers for Women for the second consecutive year”, commented Joe Cronin, Chief Human Resources Officer, ICON. “As the only CRO named in 2020, we’re proud of our unique culture at ICON and the resilience of our teams during challenging times. We are committed to ensuring that all of our employees are able to build fulfilling and successful careers at ICON and that we create an inclusive workplace where every employee can bring their best and authentic selves to work every day in pursuit of our mission to accelerate the development of medicines that improve and save patient lives.”

Earlier this year ICON was ranked in Forbes list of 2020 Best Employers for Diversity. A full list of ICON’s industry awards can be viewed here.

About ICON plc

ICON plc is a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 94 locations in 40 countries and has approximately 15,150 employees as of June 30, 2020.

Further information is available at www.iconplc. (Read more…)com.

This press release contains forward-looking statements. These statements are based on management’s current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word “expected” and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC’s website at http://www.sec.gov.

ICON/ICLR-G

Contacts

ICON Media Contact
Sophie Newington

Weber Shandwick

+44 (0)7735 580418

[email protected]